Rate of and time to symptomatic remission in first-episode psychosis in Northern Malawi: A STROBE-compliant article
- PMID: 30407306
- PMCID: PMC6250544
- DOI: 10.1097/MD.0000000000013078
Rate of and time to symptomatic remission in first-episode psychosis in Northern Malawi: A STROBE-compliant article
Abstract
Although longer duration of untreated psychosis (DUP) is associated with poor response to antipsychotic treatment, it remains unclear whether it independently influences time to symptomatic remission in first-episode psychosis (FEP). This study examined rate of symptomatic remission, and explored if DUP, premorbid functioning, global functioning, insight and socio-demographic characteristics were independently associated with time to symptomatic remission in FEP.This prospective study enrolled 126 FEP patients (aged 18-65) between June 2009 and September 2012. Subjects were followed-up monthly over 18 months after they had received antipsychotic medication. Remission in positive and negative symptoms was defined as in the Remission in Schizophrenia Working Group (RSWG) criteria. Subjects were defined as "in symptomatic remission" if they remitted in both negative and positive symptoms. At baseline, the following explanatory variables were measured: socio-demographic characteristics; DUP as short (≤5 months) and long (>5 months); premorbid functioning as deteriorating, stable poor, and stable good according to Cannon-Spoor Premorbid Adjustment Scale; global functioning as "worst (1-10) to serious (41-50)" and "moderate (51-60) to superior (91-100)," according to the Global Assessment of Functioning Scale; and insight as poor (≤8) and good (≥9) according to the Insight Scale (Birchwood). Univariate and multivariable analyses were used to generate results.Out of 126 subjects, 98 (78%) completed follow-up, of which 70 (71.4%) achieved symptomatic remission within mean duration of 8.05 (4.54) months. Besides, having long DUP and separated/divorced/widowed (adjusted hazard ratio [aHR] = 0.07, 95%CI = [0.01, 0.46]), long DUP and poor insight (aHR = 0.18, 95%CI = [0.04, 0.89]), poor insight and separated/divorced/widowed (aHR = 0.09, 95%CI = [0.01, 0.70]), deteriorating premorbid functioning (aHR = 0.47, 95%CI = [0.23, 0.97]), family history of psychiatric disorders (aHR = 0.52, 95%CI = (0.30, 0.93]), and being male (aHR = 0.47, 95%CI = [0.24, 0.92]) delayed symptomatic remission.These results propose that psychological interventions and social support for mental health problems are warranted and may enhance better response to antipsychotic medications among separated/divorced/widowed patients with long DUP or poor insight, and poor insight patients with long DUP. Deteriorating premorbid functioning, family history of psychiatric disorders and being male continue being important risk factors for poor odds of remission.
Conflict of interest statement
The authors have no conflicts of interest to disclose.
Figures
Similar articles
-
Effects of socio-demographic characteristics, premorbid functioning, and insight on duration of untreated psychosis in first-episode schizophrenia or schizophreniform disorder in Northern Malawi.Early Interv Psychiatry. 2019 Dec;13(6):1455-1464. doi: 10.1111/eip.12794. Epub 2019 Feb 1. Early Interv Psychiatry. 2019. PMID: 30706661 Free PMC article.
-
Is the association between duration of untreated psychosis and outcome confounded? A two year follow-up study of first-admitted patients.Schizophr Res. 2001 Apr 30;49(3):231-41. doi: 10.1016/s0920-9964(00)00072-4. Schizophr Res. 2001. PMID: 11356584
-
Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review.Arch Gen Psychiatry. 2005 Sep;62(9):975-83. doi: 10.1001/archpsyc.62.9.975. Arch Gen Psychiatry. 2005. PMID: 16143729
-
Prospective relationship between duration of untreated psychosis and 13-year clinical outcome: a first-episode psychosis study.Schizophr Res. 2014 Mar;153(1-3):1-8. doi: 10.1016/j.schres.2014.01.022. Epub 2014 Feb 11. Schizophr Res. 2014. PMID: 24529612
-
[Duration of untreated psychosis: A state-of-the-art review and critical analysis].Encephale. 2016 Aug;42(4):361-6. doi: 10.1016/j.encep.2015.09.007. Epub 2016 May 6. Encephale. 2016. PMID: 27161262 Review. French.
Cited by
-
Prevalence, profile and associations of cognitive impairment in Ugandan first-episode psychosis patients.Schizophr Res Cogn. 2021 Dec 30;28:100234. doi: 10.1016/j.scog.2021.100234. eCollection 2022 Jun. Schizophr Res Cogn. 2021. PMID: 35024348 Free PMC article.
-
Antipsychotic Medication in Sub-Saharan Africa: A Systematic Literature Review.J Clin Psychopharmacol. 2020 Nov/Dec;40(6):541-552. doi: 10.1097/JCP.0000000000001282. J Clin Psychopharmacol. 2020. PMID: 33009226 Free PMC article.
-
Proportion and predictors of remission and recovery in first-episode psychosis: Systematic review and meta-analysis.Eur Psychiatry. 2021 Nov 3;64(1):e69. doi: 10.1192/j.eurpsy.2021.2246. Eur Psychiatry. 2021. PMID: 34730080 Free PMC article.
-
The Association of Social Support and Symptomatic Remission among Community-Dwelling Schizophrenia Patients: A Cross-Sectional Study.Int J Environ Res Public Health. 2021 Apr 9;18(8):3977. doi: 10.3390/ijerph18083977. Int J Environ Res Public Health. 2021. PMID: 33918873 Free PMC article.
-
The association between symptomatic remission and social support in community-dwelling schizophrenia patients during COVID-19.Front Psychiatry. 2024 Jun 27;15:1404059. doi: 10.3389/fpsyt.2024.1404059. eCollection 2024. Front Psychiatry. 2024. PMID: 39077625 Free PMC article.
References
-
- Correll CU, Malhotra AK, Kaushik S, et al. Early prediction of antipsychotic response in schizophrenia. Am J Psychiatry 2003;160:2063–5. - PubMed
-
- Lee NY, Kim SH, Cho SJ, et al. A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea. Int Clin Psychopharmacol 2014;29:279–87. - PubMed
-
- Simonsen C, Faerden A, Romm KL, et al. Early clinical recovery in first-episode psychosis: symptomatic remission and its correlates at 1-year follow-up. Psychiatry Res 2017;254:118–25. - PubMed
-
- Marques TR, Arenovich T, Agid O, et al. The different trajectories of antipsychotic response: antipsychotics versus placebo. Psychol Med 2011;41:1481–8. - PubMed
-
- Emsley R, Oosthuizen PP, Kidd M, et al. Remission in first-episode psychosis: predictor variables and symptom improvement patterns. J Clin Psychiatry 2006;67:1707–12. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical